Trials / Completed
CompletedNCT03985995
Pain Response to Cannabidiol in Induced Acute Nociceptive Pain, Allodynia and Hyperalgesia By Using a Model Mimicking Acute Pain in Healthy Adults
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- University Hospital, Basel, Switzerland · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
This study is to investigate the effect of CBD on acute pain in healthy volunteers in a well-established acute pain model.
Detailed description
There are no studies investigating Cannabidiol (CBD) in an acute pain model in human beings. This is however of great clinical value because: 1. Patients are often treated insufficiently with the commonly used analgesics in acute pain therapy or the available selection of analgesics is limited by their contraindications and side-effects. 2. CBD could be an option to optimize pain therapy if the pain relief is not satisfactory. 3. CBD in contrast to ∆9-tetrahydrocannabinol (THC) has only few side effects and due to a possible dose reduction of other analgesics patients might benefit from a better side-effect profile. This study is to investigate the effect of CBD on acute pain in healthy volunteers in a well-established acute pain model.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CBD 800 mg p.o | cannabidiol solution 100 mg/ml 8 ml in single-dose containers for per os administration. After a washout period of at least two weeks, the treatment group will be receiving a single-dose of the placebo solution 8 ml as a second intervention. |
| DRUG | Placebo p.o | single dose of oral placebo solution 8 ml matched to the IMP. After a washout period of at least two weeks, the control intervention group will be receiving the cannabidiol solution 100 mg/ml 8 ml as a second intervention. |
Timeline
- Start date
- 2019-09-16
- Primary completion
- 2019-12-23
- Completion
- 2019-12-23
- First posted
- 2019-06-14
- Last updated
- 2020-01-29
Locations
1 site across 1 country: Switzerland
Source: ClinicalTrials.gov record NCT03985995. Inclusion in this directory is not an endorsement.